IART RSI Chart
Last 7 days
-2.8%
Last 30 days
-25.1%
Last 90 days
-24.4%
Trailing 12 Months
-34.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 1.6B | 1.5B | 1.5B | 1.5B |
2022 | 1.6B | 1.6B | 1.6B | 1.6B |
2021 | 1.4B | 1.5B | 1.5B | 1.5B |
2020 | 1.5B | 1.4B | 1.4B | 1.4B |
2019 | 1.5B | 1.5B | 1.5B | 1.5B |
2018 | 1.3B | 1.4B | 1.5B | 1.5B |
2017 | 1.0B | 1.0B | 1.1B | 1.2B |
2016 | 917.0M | 953.6M | 977.6M | 992.1M |
2015 | 816.2M | 831.8M | 860.6M | 882.7M |
2014 | 822.6M | 814.1M | 798.4M | 796.7M |
2013 | 831.3M | 826.7M | 829.9M | 836.2M |
2012 | 795.2M | 812.1M | 820.0M | 830.9M |
2011 | 740.4M | 755.1M | 770.7M | 780.1M |
2010 | 694.2M | 707.1M | 721.5M | 732.1M |
2009 | 0 | 663.9M | 673.2M | 682.5M |
2008 | 0 | 0 | 0 | 654.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 12, 2024 | schwartz eric | sold (taxes) | -51,595 | 35.88 | -1,438 | evp, chief legal officer & sec |
Mar 12, 2024 | davis robert t. jr. | sold (taxes) | -72,621 | 35.88 | -2,024 | evp & president, tt |
Mar 12, 2024 | mcbreen michael j. | sold (taxes) | -72,190 | 35.88 | -2,012 | evp & president, css |
Mar 12, 2024 | mosebrook jeffrey | sold (taxes) | -12,450 | 35.88 | -347 | svp, fin & princ acct officer |
Mar 11, 2024 | schwartz eric | acquired | - | - | 16,028 | evp, chief legal officer & sec |
Mar 11, 2024 | de witte jan | sold (taxes) | -7,425 | 36.22 | -205 | president & ceo |
Mar 11, 2024 | veillon-berteloot chantal | acquired | - | - | 11,758 | evp & chro |
Mar 11, 2024 | davis robert t. jr. | sold (taxes) | -87,290 | 36.22 | -2,410 | evp & president, tt |
Mar 11, 2024 | davis robert t. jr. | acquired | - | - | 20,283 | evp & president, tt |
Mar 11, 2024 | mcbreen michael j. | sold (taxes) | -142,055 | 36.22 | -3,922 | evp & president, css |
Which funds bought or sold IART recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -2.05 | 31,972,300 | 305,407,000 | 0.01% |
Mar 05, 2024 | Fisher Asset Management, LLC | reduced | -15.44 | -641,003 | 17,323,800 | 0.01% |
Mar 01, 2024 | Pineridge Advisors LLC | new | - | 19,162 | 19,162 | 0.01% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 90.89 | 30,707,700 | 56,802,600 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -7.93 | 190,237 | 4,001,030 | 0.02% |
Feb 26, 2024 | Neo Ivy Capital Management | sold off | -100 | -12,000 | - | -% |
Feb 26, 2024 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 128,000 | 1,039,000 | 0.01% |
Feb 20, 2024 | Quarry LP | reduced | -53.16 | -8,734 | 10,017 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 6.15 | 252,000 | 1,451,000 | -% |
Feb 16, 2024 | WESBANCO BANK INC | sold off | -100 | -655,073 | - | -% |
Unveiling Integra LifeSciences Holdings Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Peers (Alternatives to Integra LifeSciences Holdings Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 191.9B | 40.1B | 33.52 | 4.78 | ||||
BDX | 71.1B | 19.5B | 56.64 | 3.65 | ||||
ALGN | 24.0B | 3.9B | 53.9 | 6.21 | ||||
BAX | 21.3B | 14.8B | 8.02 | 1.44 | ||||
MID-CAP | ||||||||
BIO | 10.2B | 2.7B | -16.06 | 3.83 | ||||
HSIC | 9.4B | 12.3B | 22.59 | 0.76 | ||||
ATR | 9.3B | 3.5B | 32.86 | 2.68 | ||||
XRAY | 6.8B | 4.0B | -50.49 | 1.71 | ||||
AXNX | 3.5B | 366.4M | -571.86 | 9.5 | ||||
PDCO | 2.4B | 6.6B | 12.62 | 0.37 | ||||
SMALL-CAP | ||||||||
AHCO | 1.5B | 3.2B | -2.17 | 0.46 | ||||
ANIK | 378.1M | 166.7M | -4.57 | 2.27 | ||||
ANGO | 213.6M | 329.5M | -15.13 | 0.65 | ||||
APYX | 43.3M | 52.3M | -2.31 | 0.83 | ||||
AEMD | 4.5M | 3.7M | -0.37 | 1.19 |
Integra LifeSciences Holdings Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 3.8% | 397 | 382 | 381 | 381 | 398 | 385 | 398 | 377 | 406 | 387 | 390 | 360 | 389 | 370 | 259 | 354 | 395 | 379 | 384 | 360 | 383 |
Costs and Expenses | 1.5% | 361 | 356 | 369 | 344 | 330 | 320 | 338 | 330 | 347 | 330 | 338 | 329 | 336 | 313 | 245 | 327 | 359 | 400 | 338 | 327 | 349 |
S&GA Expenses | 0.7% | 163 | 162 | 165 | 167 | 152 | 144 | 161 | 160 | 162 | 156 | 163 | 157 | 162 | 150 | 116 | 166 | 174 | 173 | 165 | 175 | 177 |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.00 | 21.00 | - | 19.00 | 18.00 | 18.00 | 20.00 |
EBITDA Margin | -20.6% | 0.09* | 0.11* | 0.21* | 0.24* | 0.24* | 0.23* | 0.23* | 0.22* | 0.25* | 0.24* | 0.25* | 0.24* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 5.3% | 14.00 | 13.00 | 12.00 | 12.00 | 13.00 | 13.00 | 12.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 17.00 | 21.00 | 16.00 | 18.00 | 13.00 | 14.00 | 13.00 | 13.00 | 14.00 |
Income Taxes | 1116.2% | 9.00 | -0.89 | -0.36 | 6.00 | 11.00 | 9.00 | 7.00 | 6.00 | 6.00 | 8.00 | 10.00 | 22.00 | -53.83 | 9.00 | 2.00 | 2.00 | 11.00 | 0.00 | 7.00 | -7.93 | -0.62 |
Earnings Before Taxes | 55.1% | 29.00 | 19.00 | 4.00 | 30.00 | 64.00 | 59.00 | 52.00 | 39.00 | 52.00 | 51.00 | 45.00 | 67.00 | 39.00 | 42.00 | 2.00 | 11.00 | 26.00 | -27.51 | 36.00 | 25.00 | 25.00 |
EBT Margin | -30.3% | 0.05* | 0.08* | 0.10* | 0.13* | 0.14* | 0.13* | 0.12* | 0.12* | 0.14* | 0.13* | 0.13* | 0.11* | - | - | - | - | - | - | - | - | - |
Net Income | 1.7% | 20.00 | 19.00 | 4.00 | 24.00 | 53.00 | 50.00 | 45.00 | 33.00 | 45.00 | 43.00 | 35.00 | 45.00 | 93.00 | 32.00 | -0.37 | 9.00 | 15.00 | -27.61 | 30.00 | 33.00 | 25.00 |
Net Income Margin | -32.8% | 0.04* | 0.07* | 0.08* | 0.11* | 0.12* | 0.11* | 0.11* | 0.10* | 0.11* | 0.14* | 0.14* | 0.12* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 149.9% | 34.00 | 14.00 | 13.00 | 12.00 | 71.00 | 59.00 | 57.00 | 35.00 | 42.00 | 75.00 | 85.00 | 62.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 1.1% | 3,782 | 3,739 | 3,778 | 3,742 | 3,890 | 3,807 | 3,753 | 3,672 | 3,782 | 3,774 | 3,713 | 3,742 | 3,615 | 3,454 | 3,392 | 3,448 | 3,303 | 3,347 | 3,290 | 3,206 | 3,108 |
Current Assets | 3.0% | 1,058 | 1,027 | 1,051 | 1,029 | 1,161 | 1,196 | 1,137 | 1,066 | 1,154 | 1,104 | 1,032 | 1,039 | 1,237 | 1,152 | 966 | 1,009 | 858 | 884 | 869 | 823 | 775 |
Cash Equivalents | 1.0% | 276 | 274 | 309 | 307 | 457 | 512 | 447 | 407 | 513 | 470 | 397 | 409 | 470 | 396 | 361 | 358 | 199 | 208 | 176 | 157 | 139 |
Inventory | 6.4% | 390 | 366 | 354 | 351 | 325 | 311 | 320 | 328 | 317 | 327 | 324 | 328 | 310 | 308 | 359 | 338 | 316 | 303 | 297 | 287 | 280 |
Net PPE | 6.7% | 340 | 319 | 318 | 315 | 311 | 301 | 302 | 309 | 312 | 294 | 296 | 296 | 288 | 294 | 334 | 336 | 337 | 319 | 316 | 306 | 300 |
Goodwill | 1.9% | 1,055 | 1,036 | 1,043 | 1,042 | 1,039 | 978 | 990 | 1,009 | 1,013 | 1,012 | 94.00 | 1,010 | 932 | 920 | 956 | 952 | 954 | 945 | 927 | 923 | 926 |
Liabilities | 1.6% | 2,194 | 2,160 | 2,094 | 2,067 | 2,085 | 2,083 | 2,092 | 2,057 | 2,098 | 2,143 | 2,138 | 2,212 | 2,100 | 2,056 | 2,043 | 2,106 | 1,887 | 1,962 | 1,869 | 1,809 | 1,732 |
Current Liabilities | -13.7% | 307 | 356 | 377 | 282 | 321 | 304 | 296 | 316 | 340 | 333 | 319 | 412 | 401 | 255 | 212 | 246 | 331 | 303 | 315 | 288 | 263 |
Long Term Debt | 0.1% | 570 | 570 | 569 | 568 | 567 | 567 | 566 | 565 | 564 | 564 | 563 | 562 | -2.50 | 470 | 465 | 460 | - | - | - | - | - |
LT Debt, Non Current | 0.1% | 570 | 570 | 569 | 568 | 567 | 567 | 566 | 565 | 564 | 564 | 563 | 562 | -2.50 | 470 | 465 | 460 | - | - | - | - | - |
Shareholder's Equity | 0.5% | 1,588 | 1,579 | 1,683 | 1,675 | 1,804 | 1,724 | 1,661 | 1,615 | 1,685 | 1,632 | 1,575 | 1,529 | 1,515 | 1,398 | 1,349 | 1,342 | 1,417 | 1,385 | 1,421 | 1,397 | 1,376 |
Retained Earnings | 2.1% | 947 | 927 | 908 | 903 | 879 | 826 | 776 | 731 | 699 | 653 | 610 | 575 | 532 | 440 | 407 | 408 | 399 | 383 | 411 | 381 | 348 |
Additional Paid-In Capital | 3.2% | 1,302 | 1,262 | 1,284 | 1,245 | 1,277 | 1,268 | 1,260 | 1,267 | 1,265 | 1,259 | 1,249 | 1,232 | 1,291 | 1,285 | 1,279 | 1,240 | 1,214 | 1,209 | 1,198 | 1,192 | 1,193 |
Shares Outstanding | -0.9% | 80.00 | 81.00 | 81.00 | 82.00 | 83.00 | 83.00 | 83.00 | 84.00 | 85.00 | 85.00 | 85.00 | 85.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 3,257 | - | - | - | 3,916 | - | - | - | 4,969 | - | - | - | 3,370 | - | - | - | 3,946 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 119.5% | 59.00 | 27.00 | 28.00 | 26.00 | 85.00 | 68.00 | 66.00 | 44.00 | 69.00 | 83.00 | 91.00 | 69.00 | 80.00 | 70.00 | 33.00 | 21.00 | 89.00 | 64.00 | 49.00 | 29.00 | 43.00 |
Share Based Compensation | 6.1% | 6.00 | 5.00 | 5.00 | 4.00 | 6.00 | 9.00 | 7.00 | 6.00 | 6.00 | 8.00 | 16.00 | 6.00 | 5.00 | 5.00 | 5.00 | 4.00 | 6.00 | 6.00 | 6.00 | 4.00 | 5.00 |
Cashflow From Investing | -643.5% | -57.23 | -7.70 | -15.55 | -13.70 | -54.82 | 15.00 | -4.50 | -14.07 | -27.48 | -8.47 | -7.92 | -117 | -35.92 | -6.72 | -3.95 | -21.48 | -20.61 | -108 | -17.41 | -15.81 | -25.33 |
Cashflow From Financing | 86.1% | -6.89 | -49.66 | -10.69 | -162 | -97.70 | -7.64 | -13.15 | -133 | 1.00 | 2.00 | -97.47 | -3.01 | 21.00 | -33.05 | -28.55 | 162 | -81.99 | 81.00 | -13.19 | 5.00 | -84.05 |
Buy Backs | -101.0% | -1.22 | 126 | - | 151 | - | - | - | 125 | - | - | - | - | - | 4.00 | - | 92.00 | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Total revenue, net | $ 1,541,573 | $ 1,557,666 | $ 1,542,448 |
Costs and expenses: | |||
Cost of goods sold | 656,838 | 587,355 | 597,808 |
Research and development | 104,192 | 101,193 | 93,051 |
Selling, general and administrative | 656,641 | 616,316 | 637,445 |
Intangible asset amortization | 12,376 | 13,882 | 16,914 |
Total costs and expenses | 1,430,047 | 1,318,746 | 1,345,218 |
Operating income | 111,526 | 238,920 | 197,230 |
Interest income | 17,202 | 11,917 | 6,737 |
Interest expense | (51,377) | (49,594) | (50,395) |
Gain from sale of businesses | 0 | 644 | 41,798 |
Other income, net | 3,718 | 12,007 | 19,307 |
Income before income taxes | 81,069 | 213,894 | 214,677 |
Provision for income taxes | 13,328 | 33,344 | 45,602 |
Net income | $ 67,741 | $ 180,550 | $ 169,075 |
Net income per share | |||
Basic (in dollars per share) | $ 0.85 | $ 2.18 | $ 2.00 |
Diluted (in dollars per share) | $ 0.84 | $ 2.16 | $ 1.98 |
Weighted average common shares outstanding (See Note 13): | |||
Basic (in shares) | 80,089 | 82,997 | 84,698 |
Diluted (in shares) | 80,337 | 83,516 | 85,485 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 276,402 | $ 456,661 |
Short-term investments | 32,694 | 0 |
Trade accounts receivable, net of allowances of $4,879 and $4,304 | 259,327 | 263,465 |
Inventories, net | 389,608 | 324,583 |
Prepaid Expenses | 67,362 | 85,757 |
Other Current Assets | 32,643 | 31,032 |
Total current assets | 1,058,036 | 1,161,498 |
Property, plant and equipment, net | 340,199 | 311,302 |
Right of use asset - operating leases | 156,184 | 148,284 |
Intangible assets, net | 1,067,833 | 1,126,609 |
Goodwill | 1,055,462 | 1,038,881 |
Deferred tax assets, net | 46,080 | 45,994 |
Other assets | 58,194 | 57,190 |
Total assets | 3,781,988 | 3,889,758 |
Current Liabilities: | ||
Current portion of borrowings under senior credit facility | 14,531 | 38,125 |
Current portion of lease liability - operating leases | 15,284 | 14,624 |
Accounts payable, trade | 92,326 | 102,100 |
Contract liabilities | 8,540 | 7,253 |
Accrued compensation | 75,455 | 78,771 |
Accrued expenses and other current liabilities | 100,844 | 80,033 |
Total current liabilities | 306,980 | 320,906 |
Long-term borrowings under senior credit facility | 825,563 | 733,149 |
Long-term borrowings under securitization facility | 89,200 | 104,700 |
Long-term convertible securities | 570,255 | 567,341 |
Lease liability - operating leases | 166,849 | 157,420 |
Deferred tax liabilities | 35,317 | 63,338 |
Other liabilities | 199,940 | 138,501 |
Total liabilities | 2,194,104 | 2,085,355 |
Stockholders’ Equity: | ||
Preferred Stock; no par value; 15,000 authorized shares; none outstanding | 0 | 0 |
Common stock; $0.01 par value; 240,000 authorized shares; 90,920 and 90,477 issued at December 31, 2023 and 2022, respectively | 909 | 905 |
Additional paid-in capital | 1,302,484 | 1,276,977 |
Treasury stock, at cost; 12,751 and 6,823 shares at December 31, 2023 and 2022, respectively | (647,262) | (362,862) |
Accumulated other comprehensive income (loss) | (15,106) | 10,265 |
Retained earnings | 946,859 | 879,118 |
Total stockholders’ equity | 1,587,884 | 1,804,403 |
Total liabilities and stockholders’ equity | $ 3,781,988 | $ 3,889,758 |
 | Mr. Jan De Witte |
---|---|
 | www.integralife.com |
 | 3722 |